Expert Point of View: C. Kent Osborne, MD
C. Kent Osborne, MD
COMMENTING ON the ACCRU study SC-1603, press conference moderator C. Kent Osborne, MD, Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston and Co-Director of the San Antonio Breast Cancer Symposium, said: “In patients who have breast cancer, I usually start treating hot flashes with venlafaxine, but I might start with oxybutynin now.”
“It is important to select the right patient for the best drug. If a patient has a depressive component, it could be due to sleeplessness from hot flashes or the cancer itself; in that case, I would use venlafaxine,” shared Dr. Osborne. ■
DISCLOSURE: Dr. Osborne has stock and other ownership interests in GeneTex; is a consultant/advisor for AstraZeneca, Genentech/Roche, Ventana Medical Systems; has patents, royalties, or other intellectual property associated with the book Diseases of the Breast; has given expert testimony for AstraZeneca; and has received reimbursement for travel, accommodations, or expenses from Ventana Medical Systems.
OXYBUTYNIN, AN ANTICHOLINERGIC drug approved for the treatment of overactive bladder, reduced the frequency and intensity of hot flashes in women who were suffering frequent hot flashes, including breast cancer survivors who were receiving tamoxifen or aromatase inhibitors. These results of the...